[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-355564-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-355564-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","thymic-health-and-immunotherapy-outcomes-in-patients-with-cancer","Thymic health and immunotherapy outcomes in patients with cancer","","Immunotherapy has transformed cancer treatment, yet many patients derive limited benefit, creating a need for better biomarkers. Current biomarkers largely focus on tumour-intrinsic features and often overlook host immune competence. This study tests the thymus’s role in T cell maturation and shows that thymic health, measured radiographically, strongly predicts immunotherapy outcomes across a pan-cancer cohort of 3,476 patients receiving immune checkpoint inhibitors.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/thymic-health-and-immunotherapy-outcomes-in-patients-with-cancer/355564/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/thymic-health-and-immunotherapy-outcomes-in-patients-with-cancer/355564.png","ImageObject",300,407,{"name":42,"@type":43},"Taylor Morgan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-17","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why do current cancer immunotherapy biomarkers need improvement?","Question",{"text":63,"@type":64},"Many existing biomarkers focus on tumour-centric factors and do not adequately capture host immune competence. This limits the ability to predict which patients will benefit from immunotherapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What was quantified using a deep-learning framework in the study?",{"text":68,"@type":64},"The study quantified thymic health using routine computed tomography images with a deep-learning framework in a pan-cancer cohort of 3,476 patients receiving immune checkpoint inhibitors.",{"name":70,"@type":61,"acceptedAnswer":71},"How is thymic health related to immunotherapy outcomes?",{"text":72,"@type":64},"Across several cancer types, higher thymic health is associated with reduced risks of progression and all-cause mortality, and these associations remain significant across clinically relevant PD-L1 and tumour mutation burden levels.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},355564,1790548445,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099523885336,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Article  \n\n| Thymichealthandimmunotherapy outcomes inpatients with cancer |  |  |\n| --- | --- | --- |\n| [https://doi.org/10.1038/s41586-026-10243-x](https://doi.org/10.1038/s41586-026-10243-x)\u003Cbr>Received: 13 January 2025 Accepted: 5 February 2026 Published online: 18 March 2026 Open access\u003Cbr> Check for updates | Simon Bernatz1,2,3,4,15, Vasco Prudente1,2,3,15, Suraj Pai1,2,3,15, Asbjørn K. Attermann1,5,6,7,15, Alessandro Di Federico8, Andrew Rowan9, Selvaraju Veeriah9,10,11, Lars Dyrskjøt5,6, Leonard Nürnberg1,2,3, Joao V. Alessi8, Patrick A. Ott8, Elad Sharon8, Allan Hackshaw12, Nicholas McGranahan10,13, Christopher Abbosh10, Raymond H. Mak1,2, Danielle Bitterman1,2, Mark Awad8, Biagio Ricciuti8, Charles Swanton9,10,11,16, Mariam Jamal-Hanjani10,11,14,16, Nicolai J. Birkbak5,6,7,16 & Hugo J. W. L. Aerts1,2,3,16✉\u003Cbr>Although immunotherapy has revolutionized cancer treatment, many patients still experience limited benefit, highlighting the urgent need for improved biomarkers1. Although immunotherapy is founded on unleashing T cells2, most existing biomarkers remain tumour-centric and mainly overlook host immune competence. The thymus is a key immune organ that is crucial forT cell maturation, and we hypothesized that thymic functionality is associated with immunotherapy outcomes3. Here we show that thymic health, a radiographic measure of thymic functionality, is strongly associated with immunotherapy outcomes across several cancer types. Using a deep-learning framework applied to routine computed tomography images, we quantified thymichealthin a pan-cancer cohort of 3,476 patients receiving immune checkpoint inhibitors. Inpatients with non-small cell lung cancer, higher thymic health was associated with reduced risks of progression and all-cause mortality. These associations remained significant across clinically relevant levels of programmed death ligand 1 (PD-L1) and tumour mutation burden. In the prospective TRACERx lung cancer study, thymic health was positively associated with T cell receptor diversity and T cell receptor excision circles, and correlated with immune-system signalling pathways, supporting radiographic thymic health asa proxy forthymic activity and adaptive immune competence. Analysis across patients with melanoma, breast cancer or renal cancer demonstrated pan-cancer relevance. Together, these findings identify thymic health asa previously unrecognized, tumour-agnostic determinant of immunotherapy efficacy, with potential implications for patient stratification, treatment timing and the development of\u003Cbr>immune-rejuvenating strategies in precision immuno-oncology. |  |\n| In the past decade, immunotherapy has transformed cancer treat- |  | T-lymphocyte-associated protein 4 (CTLA-4), immunotherapy in the |\n| ment, markedly improving patient outcomes across diverse tumour |  | early or advanced setting has become standard of care across several |\n| types2. Notably, beyond prolonging survival, immunotherapy can pro- |  | tumour types, including melanoma5,6, non-small cell lung cancer |\n| duce durable, complete responses, even inpatients with advanced or |  | (NSCLC)7, and renal cell carcinoma (RCC)8. However, only subsets of |\n| metastatic disease4. Immunotherapy aims to unleash a host-derived |  | patients across tumour types have improved survival in response to |\n| T cell immune response against cancer cells, by blocking immune |  | ICIs9–11. |\n| regulatory pathways and overcoming cancer immune evasion. With |  | At present, biomarker research focuses on tumour-intrinsic factors, |\n| the introduction of immune checkpoint inhibitors (ICIs) that target |  | such asPD-L1 (ref. 12) or tumour mutation burden (TMB)13, but their util- |\n| programmed cell death protein 1 (PD-1), its ligand (PD-L1) or cytotoxic |  | ityas biomarkers is limited12–14, given that cancers across all biomarker |\n\n1Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA. 2Departme","cbCailrkBraBBXtI","https://ap.wps.com/l/cbCailrkBraBBXtI","pdf",16594386,26,"English","# Overview\n## Biomarker limitations and thymic hypothesis\n## Pan-cancer deep-learning assessment\n## Associations with clinical endpoints\n## Mechanistic support and pan-cancer relevance","[{\"question\":\"Why do current cancer immunotherapy biomarkers need improvement?\",\"answer\":\"Many existing biomarkers focus on tumour-centric factors and do not adequately capture host immune competence. This limits the ability to predict which patients will benefit from immunotherapy.\"},{\"question\":\"What was quantified using a deep-learning framework in the study?\",\"answer\":\"The study quantified thymic health using routine computed tomography images with a deep-learning framework in a pan-cancer cohort of 3,476 patients receiving immune checkpoint inhibitors.\"},{\"question\":\"How is thymic health related to immunotherapy outcomes?\",\"answer\":\"Across several cancer types, higher thymic health is associated with reduced risks of progression and all-cause mortality, and these associations remain significant across clinically relevant PD-L1 and tumour mutation burden levels.\"}]","Thymic health and immunotherapy outcomes in patients with cancer | PDF",1790119893,66,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1c3acb2279446bafb0bd1f9b03b44834.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8ab274c660fce4ca45631696e9356626.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5d32aa08637bdf798f01a38bcd1c281f.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/780878312f101a3d99ee98014bb53c88.webp",980,1301]